Copyright
©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 260-273
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.260
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.260
Table 1 Basic clinical, histopathological and immunohistochemical findings according to hepatitis B e antigen status
Parameters | Total | HBeAg positive | HBeAg negative |
n | 140 | 86 | 54 |
Age (yr) | 42.75 ± 11.53 | 40.30 ± 11.03 | 46.74 ± 11.29a |
Gender | |||
Male | 78 | 48 (61.5) | 30 (38.5) |
Female | 62 | 38 (61.3) | 24 (38.7) |
HBV DNA (log10IU/mL) | 7.27 ± 2.17 | 7.67 ± 2.39 | 6.65 ± 1.58a |
HBsAg (log10IU/mL) | 3.85 ± 1.04 | 4.01 ± 1.07 | 3.61 ± 0.94b |
ALT IU/L | 7.27 ± 2.17 | 155.80 ± 114.32 | 134.54 ± 98.71 |
ALT < 200 IU/L | 91 | 52 (51.7) | 39 (42.9) |
ALT ≥ 200 IU/L | 49 | 34 (69.4) | 15 (30.6) |
INR | 1.08 ± 0.21 | 1.04 ± 0.14 | 1.15 ± 0.27b |
Platelets (× 103/μL) | 226.4 ± 73.43 | 224.54 ± 70.67 | 227.59 ± 75.53 |
HAI score ≥ 9 | 61 | 38 (62.3) | 23 (37.7) |
HAI score < 9 | 79 | 48 (60.8) | 31 (39.2) |
Fibrosis ≥ 4 | 53 | 33 (62.3) | 20 (37.7) |
Fibrosis < 4 | 87 | 53 (60.9) | 34 (39.1) |
p-HBsAg | 41.05 ± 22.78 | 47.2 ± 13.98 | 31.26 ± 13.98a |
HBsAg SP1 | |||
A | 33 | 17 (51.5) | 16 (48.5) |
B | 24 | 10 (41.7) | 14 (58.3) |
C | 21 | 16 (76.2) | 5 (23.8) |
D | 16 | 10 (62.5) | 6 (37.5) |
E | 46 | 33 (71.7) | 13 (28.3) |
HBsAg SP2 | |||
Diffuse | 59 | 29 (49.2) | 30 (50.8) |
Globular | 34 | 24 (70.6) | 10 (29.4) |
Submembranous | 47 | 33 (70.2) | 14 (29.8) |
Membranous expression | |||
Present | 53 | 33 (63.3) | 20 (37.7) |
Absent | 87 | 53 (60.9) | 34 (39.1) |
Table 2 The correlation of clinicopathologic factors and hepatitis B surface antigen expression patterns with viral replication in hepatitis B e antigen positive cases
HBV DNA | HAI | Fibrosis | ||||
Parameters | < 7.67 | ≥ 7.67 | < 9 | ≥ 9 | < 4 | ≥ 4 |
n | 32 | 54 | 48 | 38 | 53 | 33 |
Age (yr) | 48.28 ± 9.6 | 35.57 ± 8.93b | 37.79 ± 10.83 | 43.47 ± 10.59a | 36.06 ± 9.39 | 47.12 ± 10.11b |
Gender | ||||||
Male | 23 (71.9) | 25 (46.3)a | 23 (47.9) | 25 (65.8) | 27 (50.9) | 21 (63.6) |
Female | 9 (28.1) | 29 (53.7) | 25 (52.1) | 13 (34.2) | 26 (49.1) | 12 (36.4) |
HBV DNA (log10IU/mL) | - | - | 8.36 ± 2.26 | 6.79 ± 2.30a | 8.15 ± 2.32 | 6.89 ± 2.34 |
HBsAg (log10IU/mL) | 3.02 ± 0.91 | 4.59 ± 0.64b | 4.28 ± 0.91 | 3.66 ± 1.61a | 4.19 ± 1.01 | 3.07 ± 1.10a |
ALT IU/L | 106.97 ± 73.55 | 184.74 ± 124.85a | 148.97 ± 61.46 | 121.46 ± 50.84 | 167.74 ± 72.1 | 136.64 ± 56.2 |
ALT< 200 IU/L | 26 (81.2) | 26 (48.1)a | 34 (70.8) | 18 (47.4)a | 32 (60.4) | 20 (60.6) |
ALT ≥ 200 IU/L | 6 (18.8) | 28 (51.9) | 14 (29.2) | 20 (52.6) | 21 (39.6) | 13 (39.4) |
INR | 1.03 ± 0.08 | 1.05 ± 0.16 | 1.03 ± 0.10 | 1.06 ± 0.17 | 1.04 ± 0.16 | 1.04 ± 0.09 |
Platelets (× 103/μL) | 217.59 ± 66.85 | 233.98 ± 80.60 | 226 ± 74.74 | 228 ± 77.51 | 224.53 ± 74.72 | 232.61 ± 77.82 |
HAI score ≥ 9 | 22 (68.8) | 16 (29.6)b | - | - | 17 (32.1) | 21 (63.6)b |
HAI score < 9 | 10 (31.2) | 38 (70.4) | - | - | 36 (67.9) | 12 (36.4) |
Fibrosis ≥ 4 | 19 (59.4) | 14 (25.9)a | 12 (25) | 21 (55.3)b | - | - |
Fibrosis < 4 | 13 (40.6) | 40 (74.1) | 36 (75) | 17 (44.7) | - | - |
p-HBsAg | 29.92 ± 10.84 | 57.44 ± 25.50b | 53.53 ± 25.12 | 39.21 ± 22.85a | 54.49 ± 26.02 | 35.49 ± 18.34b |
HBsAg SP1 | ||||||
A | 2 (6.2) | 15 (27.8)a | 11 (22.9 | 6 (15.8)a | 17 (32.1) | 0b |
B | 4 (12.5) | 6 (11.1) | 1 (2.1) | 9 (23.7) | 6 (11.3) | 4 (12.1) |
C | 6 (18.8) | 10 (18.5) | 12 (25) | 4 (10.5) | 14 (26.4) | 2 (6.1) |
D | 4 (12.5) | 6 (11.1) | 7 (14.6) | 3 (7.9) | 8 (15.1) | 2 (6.1) |
E | 16 (50) | 17 (31.5) | 17 (35.4) | 16 (42.1) | 8 (15.1) | 25 (75.8) |
HBsAg SP2 | ||||||
Diffuse | 8 (25) | 21 (38.9) | 12 (25) | 17 (44.7)a | 23 (43.4) | 6 (18.2)b |
Globular | 8 (25) | 16 (29.6) | 19 (39.6) | 5 (13.1) | 22 (41.5) | 2 (6.1) |
Submembranous | 16 (50) | 17 (31.5) | 17 (35.4) | 16 (42.1) | 8 (15.1) | 25 (75.8) |
Membranous expression | ||||||
Present | 5 (15.6) | 28 (51.9)b | 21 (43.8) | 12 (31.6) | 29 (54.7) | 4 (12.1)b |
Absent | 27 (84.4) | 26 (48.1) | 27 (56.3) | 26 (68.4) | 24 (45.3) | 29 (87.9) |
Table 3 The correlation of clinicopathologic factors and hepatitis B surface antigen expression patterns with viral replication in hepatitis B e antigen negative cases
HBV DNA | HAI | Fibrosis | ||||
Parameters | < 6.65 | ≥ 6.65 | < 9 | ≥ 9 | < 4 | ≥ 4 |
n | 23 | 31 | 31 | 23 | 34 | 20 |
Age (yr) | 48.13 ± 10.34 | 45.71 ± 12.02 | 46.52 ± 11.73 | 47.04 ± 10.92 | 45.82 ± 11.63 | 48.30 ± 10.81 |
Gender | ||||||
Male | 10 (43.5) | 20 (64.5) | 19 (61.3) | 11 (47.8) | 23 (67.6) | 7 (35)a |
Female | 13 (56.5) | 11 (35.5) | 12 (38.7) | 12 (52.2) | 11 (32.4) | 13 (65) |
HBV DNA (log10IU/mL) | - | - | 4.97 ± 1.49 | 7.56 ± 1.21a | 4.16 ± 0.97 | 3.98 ± 0.93 |
HBsAg (log10IU/mL) | 3.19 ± 0.84 | 3.92 ± 0.90 | 3.30 ± 0.8 | 3.86 ± 0.91a | 3.46 ± 0.95 | 4.03 ± 0.98 |
ALT IU/L | 96.09 ± 33.55 | 163.06 ± 50.85a | 102.55 ± 41.36 | 177.65 ± 80.65 | 126.18 ± 64.87 | 148.75 ± 58.6 |
ALT < 200 IU/L | 21 (91.3) | 18 (58.1)b | 26 (83.9) | 13 (56.5)a | 25 (73.5) | 14 (70) |
ALT ≥ 200 IU/L | 2 (8.7) | 13 (41.9) | 5 (16.1) | 10 (43.5) | 9 (26.5) | 6 (30) |
INR | 1.13 ± 0.27 | 1.17 ± 0.28 | 1.15 ± 0.3 | 1.16 ± 0.24 | 1.22 ± 0.32 | 1.04 ± 0.10b |
Platelets (× 103/μL) | 234.91 ± 80.6 | 216.31 ± 61.29 | 237.67 ± 73.34 | 206.64 ± 73.34 | 218.21 ± 71.85 | 236.5 ± 68.79 |
HAI score ≥ 9 | 2 (8.7) | 21 (67.7)b | - | - | 14 (26.5) | 9 (70)b |
HAI score < 9 | 21 (91.3) | 10 (32.3) | - | - | 20 (73.5) | 11 (30) |
Fibrosis ≥ 4 | 4 (17.4) | 16 (51.6)a | 6 (19.4) | 14 (60.9)b | - | - |
Fibrosis < 4 | 19 (82.6) | 15 (48.4) | 25 (80.6) | 9 (39.1) | - | - |
p-HBsAg | 30.39 ± 14.18 | 31.91 ± 14.04 | 28.68 ± 11.16 | 34.75 ± 16.71 | 33.21 ± 15.32 | 27.96 ± 10.93 |
HBsAg SP1 | ||||||
A | 6 (26.1) | 10 (32.3) | 13 (41.9) | 3 (13)a | 13 (38.2) | 3 (15) |
B | 5 (21.7) | 9 (29) | 5 (16.1) | 9 (39.1) | 7 (20.6) | 7 (35) |
C | 4 (17.4) | 1 (3.2) | 4 (12.9) | 1 (4.3) | 5 (14.7) | 0 |
D | 5 (21.7) | 1 (3.2) | 5 (16.1) | 1 (4.3) | 3 (8.8) | 3 (15) |
E | 3 (13) | 10 (32.3) | 4 (12.9) | 9 (39.1) | 6 (17.6) | 7 (35) |
HBsAg SP2 | ||||||
Diffuse | 11(47.8) | 19 (61.3)b | 18 (58.1) | 12 (52.2)a | 20 (58.8) | 10 (50) |
Globular | 9 (39.1) | 2 (3.2) | 9 (29) | 1 (4.3) | 7 (20.6) | 3 (15) |
Submembranous | 3 (13.1) | 10 (31.5) | 4 (12.9) | 10 (43.5) | 7 (20.6) | 7 (35) |
Membranous expression | ||||||
Present | 7 (30.4) | 13 (41.9) | 10 (32.3) | 10 (43.5) | 14 (41.2) | 6 (30) |
Absent | 16 (69.6) | 18 (58.1) | 21 (67.7) | 13 (56.5) | 20 (58.8) | 14 (70) |
Table 4 The relationship between clinicopathological factors and hepatitis B surface antigen expression patterns with viral response and serological response
HBeAg positive | HBeAg negative | ||||
VR | SR | VR | |||
Parameters | Absent | Present | Absent | Present | Present |
Age (yr) | |||||
< Mean | 11 (34.4) | 39 (72.2)b | 19 (48.7) | 31 (66)b | 24 (44.4) |
≥ Mean | 21 (65.6) | 15 (27.8) | 20 (51.43) | 16 (34) | 30 (55.6) |
Gender | |||||
Male | 21 (34.4) | 27 (50) | 24 (61.5) | 24 (48.9) | 30 (55.6) |
Female | 11 (34.4) | 27 (50) | 15 (38.5) | 23 (51.1) | 24 (44.4) |
HBV DNA | |||||
Low | 17 (53.1) | 39 (72.2)a | 16 (41) | 16 (34) | 23 (42.6) |
High | 15 (45.9) | 15 (27.8) | 23 (59) | 31 (66) | 31 (57.4) |
HBsAg | |||||
Low | 21 (65.6) | 15 (27.8)a | 21 (53.8) | 15 (31.9)b | 30 (55.6) |
High | 11 (34.4) | 39 (72.2) | 18 (46.2) | 32 (68.1) | 24 (44.4) |
ALT | |||||
< 200 IU/L | 23 (71.9) | 29 (53.7) | 29 (74.4) | 23 (48.9)a | 39 (72.2) |
≥ 200 IU/L | 9 (28.1) | 25 (46.3) | 10 (25.6) | 24 (51.1) | 15 (27.8) |
INR | |||||
Low | 15 (46.9) | 26 (48.1) | 19 (48.7) | 22 (46.8) | 39 (72.2) |
High | 17 (53.1) | 28 (51.9) | 20 (51.3) | 25 (53.2) | 15 (27.8) |
Platelets | |||||
Low | 15 (46.9) | 31 (57.4) | 20 (51.3) | 26 (55.3) | 31 (57.4) |
High | 17 (53.1 | 23 (42.6) | 19 (48.7) | 21 (44.7) | 23 (42.6) |
HAI score ≥ 9 | 13 (40.6) | 25 (46.3) | 11 (25) | 28 (59.6)a | 23 (42.6) |
HAI score < 9 | 19 (59.4) | 29 (53.7) | 28 (75) | 19 (40.4) | 31 (57.4) |
Fibrosis ≥ 4 | 17 (53.1) | 16 (29.6)a | 17 (43.6) | 16 (34) | 20 (37) |
Fibrosis < 4 | 15 (46.9) | 10 (70.4) | 22 (56.4) | 31 (66) | 34 (63) |
p-HbsAg | |||||
Low | 26 (81.3) | 25 (46.3)b | 29 (74.4) | 24 (51.1)b | 21 (38.9) |
High | 6 (18.8) | 29 (53.7) | 10 (25.6) | 23 (48.9) | 33 (61.1) |
HBsAg SP1 | |||||
A | 1 (3.1) | 16 (29.6)b | 2 (5.1) | 15 (31.9)b | 16 (29.6) |
B | 0 | 10 (18.5) | 0 | 10 (21.3) | 14 (25.9) |
C | 6 (18.8) | 10 (18.5) | 11 (28.2) | 5 (10.6) | 5 (9.3) |
D | 6 (18.8) | 4 (7.4) | 6 (15.4) | 4 (8.5) | 6 (11.1) |
E | 19 (59.4) | 14 (25.9) | 20 (51.3) | 13 (27.7) | 13 (24.1) |
HBsAg SP2 | |||||
Diffuse | 1 (3.1) | 28 (58.1)b | 2 (5.1) | 2 (57.4)b | 30 (55.6) |
Globular | 12 (37.5) | 12 (22.2) | 17 (43.6) | 7 (14.9) | 10 (18.5) |
Submembranous | 19 (59.4) | 14 (25.9) | 20 (51.3) | 13 (27.7) | 14 (25.9) |
Membranous expression | |||||
Absent | 27 (84.4) | 26 (48.1)b | 29 (74.4) | 24 (51.1)b | 21 (38.9) |
Present | 5 (15.6) | 28 (51.9) | 10 (25.6) | 23 (48.9) | 33 (61.1) |
Table 5 The association of clinicopathological factors and hepatitis B surface antigen expression patterns with viral response and serological response
HBeAg positive (n = 86) | HBeAg negative (n = 54) | ||||||||
Parameters | VR | SR | VR | ||||||
HR (95%CI) | P value1 | P value2 | HR (95%CI) | P value1 | P value2 | HR (95%CI) | P value2 | ||
Age (yr) | 0.685 (0.228-2.055) | 0.001 | 0.449 | 0.892 (0.301-2.644) | 0.007 | 0.837 | 0.936 (0.460-1.904) | 0.855 | |
Gender: male vs female | 0.581 (0.301-1.121) | 0.72 | 0.105 | 0.516 (0.251-1.062) | 0.79 | 0.072 | 2.410 (0.986-5.985) | 0.054 | |
HBV DNA (log10IU/mL) | 0.782 (0.275-2.224) | 0.003 | 0.645 | 0.707 (0.246-2.029) | 0.40 | 0.519 | 0.620 (0.255-1.508) | 0.292 | |
HBsAg (log10IU/mL) | 1.931 (0.757-4.923) | 0.001 | 0.168 | 2.252 (0.878-5.773) | 0.001 | 0.091 | 0.700 (0.294-1.669) | 0.422 | |
ALT ≥ 200 IU/L vs < 200 IU/L | 0.992 (0.476-2.068) | 0.90 | 0.982 | 1.037 (0.436-2.471) | 0.018 | 0.934 | 0.854 (0.372-1.962) | 0.710 | |
INR | 0.539 (0.271-1.072) | 0.751 | 0.078 | 0.493 (0.222-1.092) | 0.901 | 0.081 | 1.815 (0.791-4.161) | 0.159 | |
Platelets (× 103/μL) | 0.619 (0.309-1.240) | 0.194 | 0.176 | 0.538 (0.243-1.189) | 0.389 | 0.125 | 0.925 (0.452-1.892) | 0.831 | |
HAI score ≥ 9 vs < 9 | 1.566 (0.692-3.546) | 0.282 | 0.282 | 2.881 (1.170-7.094) | 0.132 | 0.021 | 6.876 (2.219-21.309) | 0.001 | |
Fibrosis ≥ 4 vs < 4 | 1.245 (0.517-2.999) | 0.021 | 0.625 | 1.079 (0.427-2.730) | 0.092 | 0.872 | 0.833 (0.326-2.125) | 0.702 | |
p-HBsAg | 3.178 (1.582-6.387) | 0.001 | 0.001 | 3.990 (1.843-8.638) | 0.001 | 0.001 | 1.089 (0.575-2.063) | 0.793 | |
SP1 | 0.899 (0.495-1.634) | 0.001 | 0.727 | 3.760 (1.742-7.861) | 0.001 | 0.531 | 0.959 (0.443-2.167) | 0.990 | |
SP2 | 0.727 (0.240-2.200) | 0.001 | 0.573 | 0.721 (0.216-2.410) | 0.001 | 0.595 | 0.996 (0.552-1.798) | 0.990 | |
Membranous expression | 1.085 (0.513-2.294) | 0.001 | 0.831 | 1.082 (0.472-2.482) | 0.001 | 0.952 | 0.692 (0.246-1.944) | 0.485 |
- Citation: Alpsoy A, Adanir H, Bayramoglu Z, Elpek GO. Correlation of hepatitis B surface antigen expression with clinicopathological and biochemical parameters in liver biopsies: A comprehensive study. World J Hepatol 2022; 14(1): 260-273
- URL: https://www.wjgnet.com/1948-5182/full/v14/i1/260.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i1.260